Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
This article reviews intravesical application of electromotive drug administration (EMDA) for the treatment of bladder cancer and the evidence in support of intravesical passive diffusion chemotherapy in the management of non-muscle invasive bladder cancer. Two recently published randomised trials adopting protocols that use EMDA to enhance urothelial transport of intravesical mitomycin-C showed it provided a therapeutical advantage and suggested that intravesical passive diffusion administration of chemotherapeutic drugs may be suboptimal. Further studies are required to demonstrate feasibility and advantage of intravesical EMDA of mitomycin-C in the wider uro-oncological community.
Di Stasi
Savino M
SM
Tor Vergata University, Department of Surgery/Urology, Rome, Italy. sdistas@tin.it
Liberati
Emanuele
E
Dutto
Lorenzo
L
Verri
Cristian
C
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D053672:Electrochemotherapy; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D009361:Neoplasm Invasiveness; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin